{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:52:21Z","timestamp":1792450341059,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/maj.0b013e3182121131","type":"journal-article","created":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T07:43:28Z","timestamp":1306914208000},"page":"409-415","source":"Crossref","is-referenced-by-count":18,"title":["Systemic Mastocytosis"],"prefix":"10.1016","volume":"342","author":[{"given":"Didem","family":"Ozdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcuk","family":"Dagdelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomris","family":"Erbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3182121131_bb0010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2003.10.035","article-title":"Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jaci.2006.04.015","article-title":"Molecular regulation of mast cell activation","volume":"117","author":"Rivera","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0020","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0030","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2009-12-259085","article-title":"Proposal for a revised classification of systemic mastocytosis","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0190-9622(88)70007-9","article-title":"Bone marrow findings in adult patients with urticaria pigmentosa","volume":"18","author":"Czarnetzki","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajh.20211","article-title":"Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience","volume":"77","author":"Hennessy","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0045","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0050","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0055","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ageing\/25.1.1","article-title":"Bone density, bone markers and bone radiological features in mastocytosis","volume":"25","author":"Johansson","year":"1996","journal-title":"Age Ageing"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0065","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/01.rlu.0000093084.55297.f5","article-title":"Super scan leading to definitive diagnosis in a patient with recurrent syncope","volume":"28","author":"Khoury","year":"2003","journal-title":"Clin Nucl Med"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0070","first-page":"142","article-title":"Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis","volume":"67","author":"van Daele","year":"2009","journal-title":"Neth J Med"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-2141.2003.04055.x","article-title":"Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis","volume":"120","author":"N\u00fa\u00f1ez-L\u00f3pez","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2500\/108854194778702946","article-title":"Tryptase: a clinical indicator of mast-cell dependent events","volume":"15","author":"Schwartz","year":"1994","journal-title":"Allergy Proc"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0085","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0090","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/10428190290021470","article-title":"Serum tryptase measurements in patients with myelodysplastic syndromes","volume":"43","author":"Sperr","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0095","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1182\/blood.V98.8.2580","article-title":"Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms","volume":"98","author":"Samorapoompichit","year":"2001","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaad.2006.09.020","article-title":"Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis","volume":"56","author":"Proelss","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0105","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0145-2126(01)00030-3","article-title":"Mast cell lineage development and phenotypic regulation","volume":"25","author":"Austen","year":"2001","journal-title":"Leuk Res"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0110","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1373\/clinchem.2006.068205","article-title":"Sensitive detection of KIT D816V in patients with mastocytosis","volume":"52","author":"Tan","year":"2006","journal-title":"Clin Chem"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","article-title":"Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge","volume":"57","author":"Horny","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0120","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0125","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"B\u00fcttner","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/1096-8652(200012)65:4<307::AID-AJH10>3.0.CO;2-F","article-title":"Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His","volume":"65","author":"Pullarkat","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0135","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene","volume":"100","author":"Yavuz","year":"2002","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0165-4608(99)00256-3","article-title":"Cytogenetic studies in patients with mastocytosis","volume":"120","author":"Swolin","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0091-6749(96)70243-9","article-title":"Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis","volume":"98","author":"Lishner","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0155","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0160","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0165","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M","article-title":"Significance of systemic mast cell disease with associated hematologic disorders","volume":"62","author":"Travis","year":"1988","journal-title":"Cancer"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0170","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0025-6196(12)62636-6","article-title":"Mast cell leukemia: report of a case and review of the literature","volume":"61","author":"Travis","year":"1986","journal-title":"Mayo Clin Proc"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0175","first-page":"739","article-title":"Mast cell sarcoma with tissue eosinophilia arising in the ascending colon","volume":"12","author":"Kojima","year":"1999","journal-title":"Mod Pathol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000245681","article-title":"Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis","volume":"195","author":"Godt","year":"1997","journal-title":"Dermatology"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000248906","article-title":"Aggressive topical corticosteroid therapy: a novel approach to mast-cell-dependent cutaneous disorders","volume":"175","author":"Lavker","year":"1987","journal-title":"Dermatologica"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0190","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","article-title":"Treatment of three patients with systemic mastocytosis with interferon alpha-2b","volume":"22","author":"Worobec","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0195","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2169\/internalmedicine.48.2294","article-title":"Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha","volume":"48","author":"Yoshida","year":"2009","journal-title":"Intern Med"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0200","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alfa: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0205","first-page":"72","article-title":"Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor","volume":"84","author":"Irani","year":"1995","journal-title":"Immunology"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0210","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1172\/JCI119336","article-title":"Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems","volume":"99","author":"Finotto","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0215","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2133.1995.tb08689.x","article-title":"Interferon-alfa in combination with corticosteroids improves systemic mast cell disease","volume":"132","author":"Delaporte","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOH.0b013e3283366c59","article-title":"Systemic mastocytosis in adults: a review on prognosis and treatment based on 342Mayo Clinic patients and current literature","volume":"17","author":"Pardanani","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0225","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0230","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0235","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0240","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00062752-200401000-00009","article-title":"Clinical, genetic, and therapeutic insights into systemic mast cell disease","volume":"11","author":"Tefferi","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0255","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.leukres.2006.04.005","article-title":"Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit","volume":"30","author":"Verstovsek","year":"2006","journal-title":"Leuk Res"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0260","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0265","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","article-title":"Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis","volume":"38","author":"Aichberger","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0270","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0275","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V","volume":"33","author":"Ustun","year":"2009","journal-title":"Leuk Res"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0280","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0285","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0290","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0295","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0300","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adultolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1097\/MAJ.0b013e3182121131_bb0305","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","article-title":"Treatment of systemic mast cell disorders","volume":"14","author":"Worobec","year":"2000","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291531137X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291531137X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T07:43:29Z","timestamp":1712475809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000296291531137X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S000296291531137X"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3182121131","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}